The acute effect of budesonide/formoterol in COPD: A multi-slice computed tomography and lung function study

European Respiratory Journal

Volumn 40, Issue 2, 2012, Pages 298-305

  De Backer, Lieve A ^a   Vos, Wim ^b   De Backer, Jan ^b   Van Holsbeke, Cedric ^b   Vinchurkar, Samir ^b   De Backer, Wilfried ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b FLUIDDA NV   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Imaging techniques in chronic obstructive pulmonary disease; Inhalation treatment; Lung function testing

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; PLACEBO;

AGED; AIRWAY RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTATIONAL FLUID DYNAMICS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG FUNCTION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; SPIROMETRY;

AGED; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDRODYNAMICS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PLACEBOS; PREDICTIVE VALUE OF TESTS; PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; TIME FACTORS;

EID: 84864767484     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00072511     Document Type: Article

References (28)

1. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742-750.
2. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664. (Pubitemid 36976273)
3. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276. (Pubitemid 32378468)
4. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85: Suppl. B, 25-31.
5. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289. (Pubitemid 27172772)
6. Jones PW. COPD: functional status, health status and primary care. Prim Care Respir J 2011; 20: 227-228.
7. Jones PW, Anderson JA, Calverley PM, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res 2011; 12: 71.
8. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
9. Adams CP, Brantner VV. Spending on new drug development. Health Econ 2010; 19: 130-141.
10. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
11. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. (Pubitemid 36173708)
12. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303. (Pubitemid 30245717)
13. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: Suppl. 5, 121S-126S. (Pubitemid 34497328)
14. Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138: 635-640.
15. Mair G, Maclay J, Miller JJ, et al. Airway dimensions in COPD: relationshipswith clinical variables. RespirMed 2010; 104: 1683-1690.
16. Diaz AA, Valim C, Yamashiro T, et al. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest 2010; 138: 880-887.
17. Lin CL, Tawhai MH, McLennan G, et al. Computational fluid dynamics. IEEE Eng Med Biol Mag 2009; 28: 25-33.
18. De Backer JW, Vos WG, Gorle CD, et al. Flow analyses in the lower airways: patient-specific model and boundary conditions. Med Eng Phys 2008; 30: 872-879.
19. De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology 2010; 257: 854-862.
20. Backer JW, Vos WG, Devolder A, et al. Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech 2008; 41: 106-113. (Pubitemid 350265902)
21. Appleton S, Poole P, Smith B, et al. Long-acting β2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001104.
22. Sin BA, Akkoca O, Saryal S, et al. Differences between asthma and COPD in the elderly. J Investig Allergol Clin Immunol 2006; 16: 44-50.
23. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124. (Pubitemid 40776231)
24. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
26. Bale G, Martinez-Camblor P, Burge PS, et al. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med 2008; 102: 1468-1472.
27. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25: 186-199. (Pubitemid 40207749)
28. Yang XL, Liu Y, Luo HY. Respiratory flow in obstructed airways. J Biomech 2006; 39: 2743-2751. (Pubitemid 44633052)